The Synergistic Repressive Effect of NF-κB and JNK Inhibitor on the Clonogenic Capacity of Jurkat Leukemia Cells

Xinli Liu¹, Jun Zhang¹, Jing Li¹, Andrew Volk³, Peter Breslin³, Jiwang Zhang³, Zhou Zhang²*

¹. Department of Biology, College of Life and Environment Science, Shanghai Normal University, Shanghai, People’s Republic of China, ². College of Life Science and Biopharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China, ³. Oncology Institute, Cardinal Bernardin Cancer Center and Departments of Pathology and Molecular/Cellular Physiology, Loyola University Chicago, Maywood, IL 60153, United States of America

*zhouzhang@hotmail.com

Abstract

Deregulation of Nuclear Transcription Factor-κB (NF-κB) and Jun N-terminal kinase (JNK) signaling is commonly detected in leukemia, suggesting an important role for these two signaling pathways in the pathogenesis of leukemia. In this study, using Jurkat cells, an acute T-lymphoblastic leukemia (T-ALL) cell line, we evaluated the effects of an NF-κB inhibitor and a JNK inhibitor individually and in combination on the proliferation, survival and clonogenic capacity of leukemic cells. We found that leukemic stem/progenitor cells (LSPCs) were more sensitive to NF-κB inhibitor treatment than were healthy hematopoietic stem/progenitor cells (HSPCs), as shown by a reduction in the clonogenic capacity of the former. Inactivation of NF-κB leads to the activation of JNK signaling in both leukemic cells and healthy HSPCs. Interestingly, JNK inhibitor treatment enhanced the repressive effects of NF-κB inhibitor on LSPCs but prevented such repression in HSPCs. Our data suggest that JNK signaling stimulates proliferation/survival in LSPCs but is a death signal in HSPCs. The combination of NF-κB inhibitor and JNK inhibitor might provide a better treatment for T-ALL leukemia by synergistically killing LSPCs while simultaneously preventing the death of normal HPCs.

Introduction

Acute T-lymphoblastic leukemia (T-ALL) is a malignant hematopoietic disorder characterized by uncontrolled proliferation and infiltration of immature T
lymphoblasts into hematopoietic tissue such as bone marrow, spleen and peripheral blood, as well as other organs [1]. Intensive chemotherapy is still the only treatment for this fatal disease. But such treatment typically kills tumor cells and normal tissue cells indiscriminately [2–5]. As a consequence, the quality of life as well as the prognosis for T-ALL patients is still very poor. More specifically targeted and less toxic forms of therapy are critically needed to improve the outcome for these patients.

Nuclear Transcription Factor-κB (NF-κB) is a family of transcription factors that regulate the expression target genes, and have been associated with diverse biological and pathological processes [6, 7]. In most types of cells, NF-κB is normally inactivated by members of the IκB family of inhibitory proteins which sequester NF-κB within the cytoplasm and subject NF-κB to proteasome-mediated degradation. Extracellular stimuli such as TNF-α and IL-1 induce the phosphorylation and activation of IκB kinases (IKKs). Activated IKKs phosphorylate IκB proteins, releasing NF-κB from inhibition by the former [6–8]. This allows the translocation of NF-κB from the cytoplasm into the nucleus, where it regulates the expression of genes responsive to it. Hundreds of NF-κB target genes have been identified; their protein products are involved in diverse key cellular and organismal processes, including cell proliferation, cell survival, the cellular stress response, innate immunity and inflammation [9].

Deregulation of the NF-κB signaling is commonly detected in many human cancers, including leukemia. It was demonstrated that NF-κB is an important mediator of immune and inflammatory reactions. In most inflammation-related cancers, the abnormal activation of NF-κB and the chronic inflammatory reaction induced by inflammatory cytokines produced by tumor cells and/or tumor environmental cells [10]. Hence, inhibition of NF-κB signaling has been proposed to be a potential therapeutic option in the treatment of cancer, especially for such inflammation-related cancers. In T-ALL, in addition to inflammatory cytokine stimulation, abnormal activation of T-cell receptor signaling, constitutive activation of Notch signaling and the inactivation of Pten signaling, all due to mutations in key components of these signal pathways, are major causes leading to the activation of NF-κB signaling in tumor cells [11, 12]. The NF-κB signaling pathway is highly activated in leukemic cells isolated from a majority of T-ALL patients [13]. Elevated NF-κB activity in leukemic cells provides a survival signal in these cells by up-regulating anti-apoptotic genes; such might be a major causal factor for the drug resistance often observed in such cancer cells. Thus, NF-κB signaling is also a critical target for anti-T-ALL therapy, especially for patients with drug-resistant tumors. NF-κB inhibitors have been tested in the clinical setting to treat T-ALL patients [14, 15] but with only limited success. The clinical use of NF-κB inhibitors in cancer therapy is limited by their side-effects and attenuated killing effects on tumor cells in vivo. The potential side-effects of NF-κB inhibitors include compromised T/B-cell immunity, inflammatory tissue damage, and an increased risk for the development of skin and liver cancer [16–18]. Interestingly, both the side-effects and reduced anti-tumor effects of NF-κB
inhibitors in vivo might be due to the excessive sensitivity of NF-κB-inactivated cells to TNF-induced activation of JNK signaling [19].

Accumulating evidence suggests that TNF can stimulate both survival and death signals within the same type of cells in a context-dependent fashion. TNF-dependent survival signals are primarily mediated by the canonical NF-κB pathway, while the TNF-induced death signal is driven by caspase-8-dependent apoptosis or RIP1/3-dependent necroptosis [20–23]. In addition, TNF also stimulates the activation of Jun N-terminal kinase (JNK) signaling [24]. JNK is a member of the mitogen activated protein kinase (MAPK) family. Interestingly, it has been demonstrated that JNK signaling also induces the dual roles of survival and death in a cell context-dependent fashion [25, 26]. JNK signaling induces cell death through phosphorylation/inactivation of Bcl2-related anti-apoptotic signaling and promotes cell proliferation/survival through AP-1 (c-Jun/Fos) complex-regulated gene expression [26]. Thus, we predict that inhibition of JNK signaling might provide improved anti-cancer therapy when combined with NF-κB inhibition, potentially synergistically killing cancer cells while protecting normal tissue cells from TNF-induced damage. To test this hypothesis, in the present study, we compared the response of Jurkat T-ALL cells and HSPCs to JNK inhibitor and NF-κB inhibitor treatment both individually and also in combination. We demonstrated that the inhibition of NF-κB induces the activation of JNK signaling in both Jurkat cells and HSPCs. JNK stimulates a survival/proliferation signal in Jurkat cells whereas it promotes death signaling in HSPCs. Our data indicate that the inhibition of JNK signaling not only significantly sensitizes T-ALL cells to NF-κB inhibitor treatment, but also protects HSPCs from the toxic effects of such treatment. Hence, the simultaneous use of an NF-κB inhibitor together with a JNK inhibitor may synergize to provide a promising novel strategy for therapeutic intervention in T-ALL.

Materials and Methods
Reagents
Recombinant human-IL-3 (rhIL-3), rhIL-6, rhSCF were purchased from eBioscience (San Diego). TNF-α was purchased from BD Biosciences. BAY11-7082 (NF-κB inhibitor) was purchased from Beyotime Institute of Biotechnology. SP600125 (JNK inhibitor) was purchased from Cell Signaling. Cell Lysis Buffer (10×) was obtained from Cell Signaling and supplemented with proteinase inhibitors and phosphatase inhibitors (Roche Diagnostics). Anti-β-actin antibody was obtained from Santa Cruz Biotechnology. Anti-p65, p-p65, JNK, p-JNK, Caspase-3, Caspase-8 and Caspase-9 primary as well as requisite secondary antibodies were obtained from Cell Signaling. Annexin-V-FITC/PI Apoptosis Detection Kit was purchased from BD Biosciences.
Cell culture
Jurkat cells, a human T-ALL cell line, were obtained from ATCC and incubated in 10% FBS RPMI-1640 medium at 37°C, 100% humidity and 5% CO₂. Peripheral blood CD34⁺ HSPCs used in this study are residual samples which were collected from healthy donors for stem cell transplantation. These cells were stored as frozen tissue in the tissue bank at the Cardinal Bernardin Cancer Center, Loyola University Chicago. IRB protocol #205719090113 allows permission for the use of these samples, as approved by the IRB committee of Loyola University Chicago. They were cultured in RPMI-1640 medium supplemented with 10% FBS, penicillin/streptomycin, 100 ng/ml rhSCF, 10 ng/ml rhIL-6, and 10 ng/ml rhIL-3.

Methyl thiazolyl tetrazolium (MTT) assay
Exponentially-growing Jurkat cells or CD34⁺ HSPCs were seeded into 96-well flat-bottomed plates in triplicate at a cell density of 1 x 10⁵ cells per ml of medium. NF-κB inhibitor BAY11-7082 and JNK inhibitor SP600125 were dissolved in DMSO and added to the each well at indicated concentrations. An equivalent volume of DMSO was used as vehicle control in all of our experiments. Forty-four hours after inhibitor treatment, 5 mg/ml of MTT was added to each well and further incubated for 4 hours in order to allow MTT to be reduced by enzymes from metabolically active cells. Subsequently, 100 μl of 10% SDS was added to each well to dissolve the formazan for 6 hours. Spectrophotometric absorbance in each well was recorded at 570 nm using a SpectraMax plate reader (Epoch Biotek technology). The absorbance reflects the number of viable cells. Triplicate experiments were performed in all our studies. All data were verified by three individual experiments.

Colony-Forming Unit (CFU) Assay
Exponentially-growing Jurkat cells or CD34⁺ HSPCs were incubated in the indicated medium at a cell density of 1 x 10⁵ cells/ml with or without inhibitors for 24 hours. All cells were isolated from the plate, centrifuged, and resuspended into 1 ml of supplemented medium; this process was repeated. Jurkat cells or CD34⁺ HSPCs were seeded into MethoCult GF M3434 (StemCell) at 1000 cells/ml, incubated at 37°C, 100% humidity and 5% CO₂ for 7 days (Jurkat cells) or 10 days (CD34⁺ HSPCs). Numbers of colonies were counted according to the manufacturer’s instructions.

Retroviral transduction
Retroviral production and infection were performed as reported [27]. MIGR1 (Cat. 27490) and pMIEG3-JunDN (Cat. 40350) retroviral plasmids were obtained through Addgene. MIGR1-DN-AP1 plasmid was generated by subcloning the JunDN fragment from pMIEG3-JunDN plasmid into the multiple clone site of MIGR1 plasmid. High titer of DN-AP1 or empty vector (Migr1) expressing...
retrovirus were produced by co-transfecting Phoenix cells with a retroviral vector containing DN-AP1 or vector-only together with packaging vectors using the Calphos Mammalian Transfection kit (Takara Bio Inc.). Retroviral supernatants were harvested 24 and 48 h. after transfection. Jurkat cells were transduced with such virus by spinoculation at 32°C, 2000 rpm for 4 h. Transduced cells (GFP+) were purified by FACS and treated with the indicated reagents for CFU assay.

Western blot analysis
Western blot analysis was performed using standard techniques. Briefly, cell lysates from Jurkat cells and CD34+ HPSCs were incubated with the indicated concentrations of BAY11-7082, SP600125 and TNF for 2 hours. Protein lysates were run on a precast 10% gradient polyacrylamide gel to detect the levels of p-NF-κB and p-JNK. Total NF-κB, JNK and β-actin were used as protein loading controls. The activities of Caspases 3, 8 and 9 were evaluated by detecting levels of the cleaved forms of Caspases 3, 8 and 9. β-actin and full-length Caspases 3, 8 and 9 were used as protein loading controls.

Wright-Giemsa staining
Exponentially-growing Jurkat cells or CD34+ HSPCs were incubated in medium with or without inhibitors at a cell density of 1 × 10^5 cells/ml for 48 hours. All cells were isolated from the plate, centrifuged, and resuspended into 1 ml. of supplemented medium. The cells were spread on clean glass slides until the slides were dry. Wright-Giemsa stain was added to the smear in sufficient quantity to cover the entire surface, and incubated at room temperature for 3–4 minutes, followed by the addition of 2.0 ml of PBS, pH 6.5 for another 6 to 8 minutes. Stained smears were rinsed with water until the edges showed a faint pinkish-red color. Cells were observed and photographed using oil immersion microscopy.

Annexin V–FITC/PI staining
Exponentially-growing Jurkat cells or CD34+ HSPCs were incubated in medium with or without inhibitors at a cell density of 1 × 10^5 cells/ml for 48 hours. Cells were then stained with FITC-conjugated Annexin-V, followed by propidium iodide (PI) staining in Annexin binding buffer following the instructions provided by the manufacturer (BD Biosciences). The number of apoptotic cells was analyzed by flow cytometry for percentages of Annexin V^-/PI^- and Annexin V^+/ PI^+ populations.

Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). Results shown are expressed as mean ± standard deviation. Differences between 2 groups were examined for statistical significance using the
Student’s t-test. When more than two groups were compared, analysis of Variance (ANOVA) is used to determine statistical significance.

Results

Jurkat cells are more sensitive to NF-κB inhibitor treatment than are normal HSPCs

Compared to normal CD34+ HSPCs, Jurkat T-ALL cells have higher NF-κB activity as shown by higher levels of p-NF-κB expression (Fig. 1A). To study the role of NF-κB on the growth and survival of T-ALL cells, Jurkat cells were treated with increasing concentrations of BAY11-7082 for 48 hours. Cell growth and death were assessed by MTT assay and Annexin-V staining, respectively. MTT analysis revealed that treatment of Jurkat cells with 100 nmol/L BAY11-7082 resulted in a slight but statistically significant decrease in absorbance (0.52 ± 0.006 vs. 0.65 ± 0.006 in vehicle control group). A marked decrease was observed at a concentration of 400 nmol/L (0.33 ± 0.01 vs. 0.65 ± 0.006 in vehicle control group) (Fig. 1B). Interestingly, increased BAY11-7082 concentration (above 400 nmol/L) did not lead to an additional MTT reduction, suggesting BAY11-7082 might only repress the growth of a portion of leukemic cells. Consistently, as shown by Annexin-V staining, a substantial degree of cell death was observed when cells were exposed to 100–400 nmol/L BAY11-7082 compared to the vehicle control group. However, death of treated cells was not further increased at BAY11-7082 concentrations >400 nmol/L. (Fig. 1C). CFU assay demonstrated a very significant dose-dependent response of Jurkat cells to BAY11-7082. In this assay, Jurkat cells were first treated with increasing dosages of BAY11-7082 for 24 hours, then seeded for CFU. As shown in Fig. 1D, 25 nmol/L of BAY11-7082 resulted in a significant decrease in CFU (about 2-fold) compared to the vehicle control group. This effect was more pronounced at concentrations of 50–400 nmol/L (Fig. 1D). The discrepancy of CFU to MTT and Annexin-V in the 25 and 50 nmol/L groups suggested that BAY11-7082 might selectively kill colonogenic cells. A parallel study was also performed using normal HSPCs. A significant growth repression in normal HSPCs by BAY11-7082 was only observed until 400 nmol/L of BAY11-7082 added, as demonstrated by decreased MTT, increased Annexin-V+ cells, and reduced CFU (Fig. 1E–G). It was known that leukemic cells are a heterogeneous population of cells. The majority of leukemic cells are partially differentiated leukemic blasts (LBs) which lose colony-forming capacity; only a small proportion of leukemic cells are leukemia stem/progenitor cells (LSPCs) which can form colonies (20–25% of Jurkat cells, Fig. 1D). Our results show that a low-dose (<400 nM/L) of BAY11-7082 was sufficient to inhibit the CFU ability in Jurkat cells, suggesting that LSPCs are highly sensitive to NF-κB inhibitor treatment. In contrast, normal HSPCs are relatively tolerant to such lower-dose treatment. Interestingly, LBs are resistant to at least a 7–8 times higher dose of BAY11-7082 than are LSPCs.
NF-κB inhibitor induces JNK activation, and TNF-stimulated JNK activation is independent of NF-κB signaling

Studies demonstrated that many tissue cells in which NF-κB was inactivated showed increased sensitivity to TNF-induced cell death, resulting in severe tissue damage. Studies using knockout mice showed that, in skin and liver, NF-κB inactivation even caused cancer to develop. All such effects of NF-κB inhibition are associated with TNF-induced increased activation of JNK signaling \cite{16–18}. To study whether NF-κB inhibition also increases TNF-JNK activity in leukemic cells and HSPCs, we examined JNK activity after BAY11-7082 treatment. We found that in response to increased concentrations of BAY11-7082, p-p65 levels were repressed, suggesting an effect for the inhibitor. Complete suppression of p-p65 was detected at 200 nmol/L of BAY11-7082 (Fig. 2A). As expected, we found that expression of p-JNK was increased in both Jurkat cells and normal HSPCs in response to TNF and/or BAY11-7082 treatment. In addition, NF-κB inhibition did not repress TNF-stimulated JNK signaling. These data suggest that: 1)
inactivation of NF-κB may induce JNK activation; and 2) TNF-stimulated JNK activation is independent of NF-κB signaling (Fig. 2B, C).

**JNK inhibitor SP600125 inhibits the growth of Jurkat cells but has little effect on normal HSPCs**

Consistent with the results of our previous studies in AML cells, TNF induced short-duration JNK activity in Jurkat cells but extended JNK activation in HSPCs (Fig. 3A, B). The increased JNK activity in both leukemic cells and HSPCs after NF-κB inhibitor treatment prompted us to inquire about the role of JNK signaling in such cells. Firstly, we determined the optimal concentration of the JNK inhibitor SP600125 by treating Jurkat cells and CD34+ HSPCs with TNF to induce JNK signaling activation and then treated with increasing concentrations of the inhibitor. p-JNK was activated by TNF in both Jurkat cells and CD34+ HSPCs; levels were down-regulated by SP600125 in a dose-dependent fashion. Complete repression of p-JNK was achieved in Jurkat cells and CD34+ HSPCs at
an SP600125 concentration of 20 µmol/L (Fig. 3C, D). Consistent with these data, dosage-dependent inhibitory effects of SP600125 on the growth and survival of Jurkat cells were observed. We found that 10 µmol/L and 20 µmol/L SP600125 resulted in significant inhibitory effects on the growth and survival of Jurkat cells. After 48 hours of incubation, A570 values of $0.38 \pm 0.04$ and $0.33 \pm 0.03$ were obtained for the 10 µmol/L and 20 µmol/L SP600125 treatment groups.
respectively; these values are significantly reduced compared to the vehicle control group (0.71 ± 0.007) (Fig. 3E). Consistently, cell death in the 10 μmol/L and 20 μmol/L SP600125 treatment groups was significantly increased (18.6 ± 1.53% and 22.7 ± 0.58%, respectively) compared to the vehicle control group (3.6 ± 0.21%) (Fig. 3F). Furthermore, greater than 50% reduction in Jurkat cell CFUs was observed with an SP600125 concentration of as low as 2.5 μmol/L, and no CFUs were detected when 20 μmol/L SP600125 was used (Fig. 3G). In contrast, such dosages of SP600125 had no effect on the survival, growth or CFU ability of CD34+ normal HSPCs. The reduction of CFUs for CD34+ HSPCs at 30 μmol/L SP600125 might be due to a non-specific activity of this inhibitor (Fig. 3H–J) because a complete inhibition of JNK signaling can be achieved at 20 μmol/L SP600125 (Fig. 3C, D). Collectively, these data suggest that clonogenic LSPCs are highly sensitive to SP600125 treatment compared to partially-differentiated leukemic blasts (LBs), while normal HSPCs are relatively tolerant to treatment with this inhibitor.

JNK inhibitor enhances the repressive effect of NF-κB inhibitor on Jurkat cells by promoting extrinsic apoptosis

The findings detailed above imply that both JNK and NF-κB signals are required for the proliferation and survival of leukemic cells, especially LSPCs. Thus the inactivation of both JNK and NF-κB signaling might act in a synergistic manner to kill leukemic cells. To test this hypothesis, Jurkat cells were treated with 200 nmol/L BAY11-7082, 10 μmol/L SP600125 or both of these together in combination for 48 hours. Cell growth and death analysis revealed that the combination treatment yielded a more significant inhibitory/killing effect on leukemic cells compared to individual inhibitor treatment groups. The MTT absorbance in the combination group was 0.38 ± 0.02, significantly lower than either BAY11-7082 or SP600125 individual inhibitor groups, which were 0.72 ± 0.04 and 0.67 ± 0.008, respectively (Fig. 4A). The percentages of apoptotic cells were 17.82 ± 0.42% and 16.12 ± 0.92%, respectively, in 200 nmol/L BAY11-7082 and 10 μmol/L SP600125-treated groups, values which are significantly higher than the vehicle control group (3.88 ± 0.18%). The percentage of apoptotic cells in the combined inhibitor group was 66.91 ± 3.11%, which is significantly higher compared to the individual inhibitor-treated groups (Fig. 4B). Furthermore, the combination of these inhibitors completely inhibited the formation of colonies whereas a few colonies can still be detected in individual inhibitor treatment groups (Fig. 4C). To verify that the inhibitory effects of SP600125 on T-ALL cells are due to the specific inhibition of JNK signaling, Jurkat cells were transduced with DN-AP1 to repress JNK signaling by antagonizing AP1-mediated transcription downstream of JNK. The transduced cells were treated with DMSO, 10 μmol/L SP600125 or 200 nmol/L BAY11-7082 for CFU assay. Migr1-vector-transduced cells were studied in parallel as controls. A significant reduction of CFU was observed in DN-AP1-transduced cells compared to Migr1-transduced cells. Consistent with SP600125 treatment, DN-
AP1-transduced cells are more sensitive to BAY11-7082 treatment compared to Migr1-transduced cells. Ten μmol/L SP600125 significantly repressed the CFU of Migr1-transduced cells but not DN-AP1-transduced cells, suggesting the JNK-specific effects of SP600125 at dosages used in our experiments (Fig. 4D). Collectively, these results indicate that a combination of JNK inhibitor and NF-κB inhibitor results in a synergistic inhibitory effect on LSPC growth/survival by inducing increased apoptosis.

The apoptotic death of Jurkat cells was further verified by cell morphologic study. We found that, after 48 hours of incubation with the indicated concentrations of NF-κB inhibitor or JNK inhibitor, compared to the vehicle control group, the number of apoptotic cells, characterized by segmented nuclei, nuclear side shift, pycnosis, karyorrhexis and apoptotic bodies was significantly increased in both of the individual inhibitor-treated groups; (Fig. 4E). We determined that combined NF-κB and JNK inhibitor treatment induced the activation of Caspases 8 and 3 but not Caspase 9. These data demonstrate that
JNK inhibition synergizes with NF-κB inhibition to restrict the growth of Jurkat cells by inducing extrinsic apoptotic signaling (Fig. 4F).

JNK inhibitor protects normal human HSPCs from repression by NF-κB inhibitor

As shown is Fig. 1E–G, 400 nmol/L of NF-κB inhibitor significantly repressed the growth, induced death and inhibited CFUs in healthy human HSPCs. We have reported that JNK inhibition prevents normal murine HSPCs from NF-κB inhibitor- induced cell death. To study whether JNK inhibition also protects healthy human HSPCs from the inhibitory effects NF-κB inhibitor, human CD34+ HSPCs were treated with 400 nmol/L of BAY11-7082 or 10 µmol/L of SP600125 individually or in a combination including both. Cell growth, cell death and CFU were examined after 48 hours of treatment. While 400 nmol/L of NF-κB inhibitor significantly repressed the growth, induced death and inhibited CFUs in HSPCs, we found that such effects were largely prevented by treatment with 10 µmol/L of JNK inhibitor (Fig. 5A–C). These results indicate that JNK inhibition also protects normal human HSPCs from the repressive effects of NF-κB inhibition.

Discussion

Elevated NF-κB activity has often been detected in a variety of types of human malignancy, especially in gliomas, prostate cancer, inflammatory intestinal tumors and leukemias/lymphomas. In these instances, activated NF-κB signaling has been conjectured to contribute to tumor development and progression by promoting the proliferation and survival of tumor cells [28–31]. Thus, it was suggested that inhibition of NF-κB signaling is a potentially effective treatment option for these malignancies, inducing longer disease remission and improved patient quality of life and survival [32]. However, the therapeutic use of NF-κB inhibitors can only be evaluated when: 1) the critical role of NF-κB activation in tumor cell growth is firmly confirmed by pre-clinical evidence; and 2) the side-effects of the inhibitors can be minimized.

The role of NF-κB activation in the pathogenesis of hematopoietic malignancies is better suited for study. In B-lymphocytic malignancies, activating mutations of positive regulators or inactivating mutations of negative regulators of NF-κB signaling have been reported, specifically in myeloma, activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), and mucosa-associated lymphoid tissue (MALT) lymphoma, all of which result in constitutive NF-κB activation [33, 34]. These malignant tumor cells are addicted to NF-κB signaling for their proliferation and survival. Thus, NF-κB inhibitors have been evaluated in the treatment of B-ALL/lymphomas, and they showed very promising effects. However, in AML and T-ALL/lymphomas, despite the increased activation of NF-κB in such tumor cells, particularly in LSPCs, mutations of NF-κB signaling components have rarely been reported [35]. The increased NF-κB activity in such
tumor cells is induced primarily by: 1) other oncogenic mutations, such as activating mutations; 2) microenvironmental factors secreted by tumor cells or tumor stromal cells; and/or 3) chemotherapeutic-induced DNA damage [36, 37]. Thus, inhibition of NF-κB signaling alone might not be sufficient to eliminate most leukemic cells because other survival/proliferative signaling might be also activated by these oncogenic mutations and microenvironmental factors. Our recent studies with AML cells suggested that TNF-JNK signaling is one such signaling pathway which promotes the survival/proliferation of leukemic cells when NF-κB signaling is repressed. We demonstrated that TNF secreted by AML cells stimulates the survival/proliferation of tumor cells by inducing the activation of NF-κB and JNK, two parallel survival/proliferation signaling pathways. In addition, TNF represses normal hematopoiesis in mice by inducing the activation of JNK-mediated death signaling. Such TNF-JNK death signaling induces tissue damage, which might be the major causes of the side-effects of NF-κB inhibitor treatment. We concluded that inhibition of both NF-κB and JNK signaling should provide a more promising treatment strategy for TNF-expressing AML by synergistically killing leukemic cells while simultaneously providing protection to normal HSPCs [27].

In the current study, we extended our approach to test whether JNK also stimulates NF-κB-independent survival/proliferation signaling in T-ALL cells. Consistent with the conclusions we drew from our studies of AML [37], we found that NF-κB signaling is activated in Jurkat T-ALL cells. Compared to normal HSPCs, LSPCs in Jurkat cells are more highly sensitive to NF-κB-induced cell death. However, inactivation of NF-κB signaling induces the activation of JNK
signaling which compromises the killing effects of NF-κB inhibition in Jurkat cells and promote apoptosis in normal HSPCs. Fortunately, inactivation of JNK signaling induces apoptosis in T-ALL cells with negligible influence on normal HSPCs at the optimal concentration of JNK inhibitor, providing a dosage window for us to use JNK inhibitors in the treatment of T-ALL. When used together with an NF-κB inhibitor, the JNK inhibitor amplifies the lethal effects on tumor cells by inducing extrinsic apoptotic signaling while at the same time protecting HSPCs from JNK-mediated cell death.

It is necessary to mention that several previous studies suggested that Jurkat cells are relatively resistant to NF-κB inhibitor treatment. Only minimal apoptosis and growth repression were observed (significance not shown) when 2–3 μmol/L of BAY11-8072 was used [38, 39]. Consistent with these studies, we found that BAY11-7082 induces apoptosis in <20% (4 to 5 times vehicle control) of Jurkat cells even at a concentration as high as 2–3 μmol/L. We believe that such subtle changes can be detected by more sensitive assays and carefully comparisons. Our study demonstrated that a growth repressive effect of BAY11-8072 on CFU in Jurkat cells can be detected at as low as 25 nmol/L and maximal repression can be achieved at 400 nmol/L BAY11-8072. Given a 20–25% frequency of LSPCs in Jurkat cells, as shown by CFU assay, we speculate that BAY11-8072 selectively eliminates LSPCs with limited effects on non-clonogenic LBs. Most importantly, we found that combination treatment using both BAY11-8072 and SP600125 together can completely eliminate LSPCs at a dosage that does not detectably influence the clonogenic capacity of normal HSPCs. Because LSPCs are the cause of leukemia relapse and drug resistance, effective elimination of LSPCs is a very important aspect of successful anti-leukemic treatment. In summary, our findings provide insight into the anti-T-ALL leukemic effect of NF-κB and JNK combined-inhibitor treatment and support further evaluation of these molecules as promising agents for novel therapeutic interventions with other chemotherapeutic agents for the treatment of such fatal diseases as T-ALL.

Author Contributions
Conceived and designed the experiments: XLL ZZ JWZ.Performed the experiments: XLL JZ JL AV. Analyzed the data: XLL. Contributed reagents/materials/analysis tools: XLL. Wrote the paper: XLL JWZ PB.

References
1. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, et al. (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203–1210.
2. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, et al. (2004) Oscillations in NF-κB signaling control the dynamics of gene expression. Science 306(5696): 704–708.
3. Fuchs O (2004) Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapy agents for the treatment of hematologic malignancies. Curr Pharmacol 3: 98–122.
4. McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11: 164–179.

5. Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C (2012) The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 3: 525–534.

6. Ferrando AA (2009) The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 1: 353–361.

7. Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM (2004) Constitutive NF-kappab/Rel activation in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma 45(6): 1181–1184.

8. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801–847.

9. Hayden MS, Ghosh S (2004) Signaling to NF-kB. Genes Dev 18: 2195–2224.

10. Palomero T, Dominguez M, Ferrando AA (2008) The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 7: 965–970.

11. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, et al. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98(8): 2301–2307.

12. Hernandez-Illaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, et al. (2011) Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117: 5058–5066.

13. Javelaud D, Besancon F (2001) NF-kappa B activation results in rapid inactivation of JNK in TNF-α treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. Oncogene 20: 4365–4372.

14. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749–759.

15. Maniatis TA (1999) A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 13: 505–510.

16. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103(2): 239–52.

17. Chang L, Karin M (2001) Mammalian MAP kinase signaling cascades. Nature 410: 37–40.

18. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ (2002) Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32: 201–205.

19. Schioppa T, Moorea R, Thompsona RG, Rosserb EC, Kulbea H, et al. (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA 108: 10662–10667.

20. Salem K, Brown CO, Schibler J, Goel A (2013) Co mbination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol 41: 209–218.

21. Jiang XJ, Huang KK, Yang M, Qiao L, Wang Q, et al. (2012) Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways. Cancer Letters 326: 135–142.

22. Katsman A, Umezawa K, Bonavida B (2009) Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 15: 792–808.

23. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, et al. (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nature immunology 6: 1087–1095.

24. Omori E, Matsumoto K, Sanjo H, Sato S, Akira S, et al. (2006) TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J Biol Chem 281: 19610–19617.

25. Kaiser WJ, Upton JP, Long AB, Rosanoff DL, Daley-Bauer LP, et al. (2011) RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368–372.

26. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, et al. (2011) cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 43: 449–463.
27. Andrew Volk, Jing Li, Junping Xin, Dewen You, Jun Zhang, et al. (2014) Sensitizing TNF-Expressing Acute Myeloid Leukemia Cells to NF-κB Inhibitor Treatment by Blocking TNF-JNK-AP1 Signaling. JEM Jun 2 211(6): 1093–108.

28. Knight B, Yeoh CT, Husk KL, Tina LY, Abrahama LJ, et al. (2000) Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 192: 1809–1818.

29. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5: 828–831.

30. Oguma K., Oshima H, Oshima M (2010) Inflammation, tumor necrosis factor and Wnt promotion in gastric cancer development. Future Oncol 6: 515–526.

31. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. (2004) IKK beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3): 285–96.

32. Prasad S, Ravindran J, Aggarwal BB (2010) NF-κB and cancer: how intimate is this relationship. Mol Cell Biochem 36(1–2): 25–37.

33. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12): 1861–74.

34. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, et al. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa- associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–57.

35. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, et al. (2006) Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116(11): 3042–9.

36. Karin M (2009) NF-κB: A network hub controlling immunity, inflammation, and cancer. Cold Spring Harb Perspect Biol 1: a000141.

37. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823–835.

38. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, et al. (2002) Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. Sep 1; 100(5): 1828–34.

39. Dai Y, Rahmani M, Dent P, Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol. Jul; 25(13): 5429–44.